|
Sign In to gain access to subscriptions and/or personal tools.
|
Orthomolecular Oncology Review: Ascorbic Acid and Cancer 25 Years Later
Michael J. González
University of Puerto Rico, Medical Sciences Campus, Graduate School of Public Health, Department Human Development, Nutrition Program, PO Box 365067, San Juan, PR 00936-5067 mgonzalez{at}rcm.upr.edu.
Jorge R. Miranda-Massari
School of Pharmacy, Department of Pharmacy Practice, University of Puerto Rico, San Juan.
Edna M. Mora
School of Medicine, Surgery Division, University of Puerto Rico, and Puerto Rico Cancer Center, San Juan, Puerto Rico.
Angelik Guzmán
RECNAC II Project, University of Puerto Rico, Medical Sciences Campus, School of Public Health, Department of Human Development, Nutrition Program, San Juan, Puerto Rico.
Neil H. Riordan
Ai Dan Incorp, Tempe, Arizona.
Hugh D. Riordan
Joseph J. Casciari
James A. Jackson
Center for the Improvement of Human Functioning, Wichita, Kansas.
Angel Román-Franco
Department of Pathology, University of Puerto Rico, San Juan.
The effect of ascorbic acid on cancer has been a subject of great controversy. This is a follow-up review of the 1979 article by Cameron, Pauling, and Leibovitz published in Cancer Research. In this updated version, the authors address general aspects of ascorbic acid and cancer that have been presented before, while reviewing, analyzing, and updating new existing literature on the subject. In addition, they present and discuss their own mechanistic hypothesis on the effect of ascorbic acid on the cancer cell. The objective of this review is to provide an updated scientific basis for the use of ascorbic acid, especially intravenously as adjuvant treatment in pharmacological nutritional oncology.
Key Words: vitamin C intravenous ascorbic acid cancer tumor growth nontoxic chemotherapy antioxidant prooxidant
Integrative Cancer Therapies, Vol. 4, No. 1,
32-44 (2005)
DOI: 10.1177/1534735404273861

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
D. Campos, C. Austerlitz, R. R. Allison, H. Povoa, and C. Sibata
Nutrition and Orthomolecular Supplementation in Lung Cancer Patients
Integr Cancer Ther,
December 1, 2009;
8(4):
398 - 408.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Hoffer, M. Levine, S. Assouline, D. Melnychuk, S. J. Padayatty, K. Rosadiuk, C. Rousseau, L. Robitaille, and W. H. Miller Jr
Phase I clinical trial of i.v. ascorbic acid in advanced malignancy
Ann. Onc.,
November 1, 2008;
19(11):
1969 - 1974.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Bahadorani, P. Bahadorani, J. P. Phillips, and A. J. Hilliker
The Effects of Vitamin Supplementation on Drosophila Life Span Under Normoxia and Under Oxidative Stress
J Gerontol A Biol Sci Med Sci,
January 1, 2008;
63(1):
35 - 42.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Hickey, L. Noriega, and H. Roberts
Re: Multivitamin Use and Risk of Prostate Cancer in the National Institutes of Health AARP Diet and Health Study
J Natl Cancer Inst,
October 3, 2007;
99(19):
1491 - 1492.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Li and H. E. Schellhorn
New Developments and Novel Therapeutic Perspectives for Vitamin C
J. Nutr.,
October 1, 2007;
137(10):
2171 - 2184.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Gonzalez and J. R. Miranda-Massari
Advances in Vitamin C Research
Integr Cancer Ther,
March 1, 2006;
5(1):
7 - 8.
[PDF]
|
 |
|

|
 |

|
 |
 
R. W. Moss
Should Patients Undergoing Chemotherapy and Radiotherapy Be Prescribed Antioxidants?
Integr Cancer Ther,
March 1, 2006;
5(1):
63 - 82.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. H. Dashwood, M. C. Myzak, and E. Ho
Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention?
Carcinogenesis,
February 1, 2006;
27(2):
344 - 349.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. I. Block
Antioxidants in the News
Integr Cancer Ther,
December 1, 2005;
4(4):
271 - 273.
[PDF]
|
 |
|
|